- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging tyrosine kinase inhibitors for esophageal cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 18, Issue 2, Pages 219-230
Publisher
Informa Healthcare
Online
2013-06-03
DOI
10.1517/14728214.2013.805203
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma.
- (2017) J. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): Results of a phase II trial.
- (2017) J. J. Knox et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.
- (2017) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.
- (2017) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
- (2012) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
- (2012) J H Yi et al. BRITISH JOURNAL OF CANCER
- Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
- (2012) H. H. Yoon et al. CLINICAL CANCER RESEARCH
- Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
- (2012) M. Terashima et al. CLINICAL CANCER RESEARCH
- Metastatic Human Papillomavirus–Positive Nasopharyngeal Carcinoma With an Unusual Pattern of Aggressive Hematogenous Spread
- (2012) Sonali M. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic Review and Meta-analysis of the Influence of HER2 Expression and Amplification in Operable Oesophageal Cancer
- (2012) David S. Y. Chan et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe
- (2012) Jordan M. Schmitt et al. Journal of Thoracic Oncology
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
- (2012) P. van Hagen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
- (2011) S. Iqbal et al. ANNALS OF ONCOLOGY
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
- (2011) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review
- (2011) Terence C. Chua et al. INTERNATIONAL JOURNAL OF CANCER
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Neck Ecchymosis in Amyloidosis
- (2011) Dries Deeren JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
- (2010) David H. Ilson et al. CANCER
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
- (2010) Matthew D. Galsky et al. INVESTIGATIONAL NEW DRUGS
- Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
- (2010) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
- (2010) Weijing Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer
- (2010) Cristina P. Rodriguez et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Pilot Study of Gefitinib, Oxaliplatin, and Radiotherapy for Esophageal Adenocarcinoma
- (2009) Milind Javle et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer
- (2009) G. Yu et al. CLINICAL CANCER RESEARCH
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
- (2009) Narikazu Boku et al. LANCET ONCOLOGY
- Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer
- (2009) Chia Huey Ooi et al. PLoS Genetics
- Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma
- (2008) J B Tuynman et al. BRITISH JOURNAL OF CANCER
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
- (2008) Joel Tepper et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA expression profiles of esophageal cancer
- (2008) Andrew Feber et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
- (2008) T. Bachleitner-Hofmann et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started